A systemic review of intravenous immunoglobulin G treatment in women with recurrent implantation failures and recurrent pregnancy losses
| Autor: | Srividya Seshadri, Wael Saab, Changsheng Huang, Nayoung Sung, Lujain Alsubki, Joanne Kwak-Kim |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Abortion Habitual Pediatrics medicine.medical_specialty media_common.quotation_subject medicine.medical_treatment Immunology Fertility Reproductive technology 03 medical and health sciences 0302 clinical medicine Pregnancy medicine Humans Immunologic Factors Immunology and Allergy Dosing Randomized Controlled Trials as Topic media_common Genetic testing 030219 obstetrics & reproductive medicine medicine.diagnostic_test business.industry Immunoglobulins Intravenous Obstetrics and Gynecology Immunotherapy biochemical phenomena metabolism and nutrition medicine.disease 030104 developmental biology Immune System Diseases Reproductive Medicine Etiology bacteria Female business Infertility Female Embryo quality |
| Zdroj: | American Journal of Reproductive Immunology. 85 |
| ISSN: | 1600-0897 1046-7408 |
| DOI: | 10.1111/aji.13395 |
| Popis: | Over the last few decades, the advancement in reproductive technologies and protocols to improve embryo quality through culture techniques and genetic testing to eliminate chromosomally abnormal embryos resulted in better pregnancy rates and outcomes after fertility treatments. Unfortunately, some patients still struggle with recurrent implantation failures (RIFs) and recurrent pregnancy losses (RPLs). Immune etiologies have been attributed to play an important role in some of those patients. Maintaining a pre-conceptional anti-inflammatory environment for implantation and pregnancy continuation yields superior results. Intravenous immunoglobulin G (IVIG) treatment has been reported to enhance reproductive outcome in patients with RIF and RPL with immune dysregulations. In this systemic review, we analyzed outcomes of IVIG trials for RIF and RPL, its mechanism of action, dosing, administration, side-effects, and evidence for its use in women with RIF and RPL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text